(Q24201307)

dementia with Lewy bodies

inferred from title

1 reference

Cochrane Database of Systematic Reviews

inferred from title

cognitive dysfunction

1 reference

Michal Rolinski

1

0 references

Chris Fox

series ordinal

2

0 references

Ian Maidment

series ordinal

3

0 references

Rupert McShane

series ordinal

4

0 references

publication date

14 March 2012

0 references

published in

0 references

cites work

Donepezil for cognitive impairment in Parkinson's disease: a randomised controlled study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006504.PUB2

Rivastigmine for dementia associated with Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006504.PUB2

Rivastigmine in the treatment of dementia associated with Parkinson's disease: effects on activities of daily living

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006504.PUB2

Efficacy of rivastigmine on executive function in patients with Parkinson's disease dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006504.PUB2

Benefits of rivastigmine on attention in dementia associated with Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006504.PUB2

Randomized placebo-controlled trial of donepezil in cognitive impairment in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006504.PUB2

Dementia with lewy bodies: findings from an international multicentre study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006504.PUB2

Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006504.PUB2

Effects of rivastigmine on cognitive function in dementia with lewy bodies: a randomised placebo-controlled international study using the cognitive drug research computerised assessment system

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006504.PUB2

Donepezil for dementia in Parkinson's disease: a randomised, double blind, placebo controlled, crossover study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006504.PUB2

Cognitive, psychiatric and motor response to galantamine in Parkinson's disease with dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006504.PUB2

Rivastigmine versus placebo in hyperhomocysteinemic Parkinson's disease dementia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006504.PUB2

Successful use of donepezil for the treatment of psychotic symptoms in patients with Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006504.PUB2

Donepezil as add-on treatment of psychotic symptoms in patients with dementia of the Alzheimer's type

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006504.PUB2

Effects of a central cholinesterase inhibitor on reducing falls in Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006504.PUB2

Effects of rivastigmine in Alzheimer's disease patients with and without hallucinations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006504.PUB2

Donepezil in the treatment of hallucinations and delusions in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006504.PUB2

Effects of rivastigmine on the quantitative EEG in demented Parkinsonian patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006504.PUB2

Efficacy of low-dose donepezil for visual hallucinations in a patient with dementia with Lewy bodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006504.PUB2

Rivastigmine (Exelon) for dementia in patients with Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006504.PUB2

Economic evaluation of cholinesterase inhibitor therapy for dementia: comparison of Alzheimer's disease and Dementia with Lewy bodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006504.PUB2

Efficacy and safety of donepezil in the treatment of executive dysfunction in Parkinson disease: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006504.PUB2

Efficacy and safety of galantamine (reminyl) for dementia in patients with Parkinson's disease (an open controlled trial).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006504.PUB2

Cardiovascular effects of donepezil in patients with dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006504.PUB2

What happens when donepezil is suddenly withdrawn? An open label trial in dementia with Lewy bodies and Parkinson's disease with dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006504.PUB2

Efficacy and safety of donepezil in patients with dementia with Lewy bodies: preliminary findings from an open-label study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006504.PUB2

Safety and tolerability of rivastigmine capsule with memantine in patients with probable Alzheimer's disease: a 26-week, open-label, prospective trial (Study ENA713B US32).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006504.PUB2

Cholinesterase inhibitors in advanced Dementia with Lewy bodies: increase or stop?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006504.PUB2

Rivastigmine in the treatment of parkinsonian psychosis and cognitive impairment: preliminary findings from an open trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006504.PUB2

Neurovascular Coupling in Parkinson's Disease Patients: Effects of Dementia and Acetylcholinesterase Inhibitor Treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006504.PUB2

Better cognitive and psychopathologic response to donepezil in patients prospectively diagnosed as dementia with Lewy bodies: a preliminary study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006504.PUB2

Improved visual hallucination by donepezil and occipital glucose metabolism in dementia with Lewy bodies: the Osaki-Tajiri project

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006504.PUB2

A comparison of the efficacy of donepezil in Parkinson's disease with dementia and dementia with Lewy bodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006504.PUB2

Response to rivastigmine or donepezil in Alzheimer's patients with symptoms suggestive of concomitant Lewy body pathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006504.PUB2

The beneficial effect of cholinesterase inhibitors on patients suffering from Parkinson's disease and dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006504.PUB2

Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006504.PUB2

A systematic review of prevalence studies of dementia in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006504.PUB2

Differences in neuropathologic characteristics across the Lewy body dementia spectrum

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006504.PUB2

Word-list generation deficits in dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006504.PUB2

Cognitive decline correlates with neuropathological stage in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006504.PUB2

Current treatment of dementia with Lewy bodies and dementia associated with Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006504.PUB2

Cortical Lewy body disease and Parkinson's disease dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006504.PUB2

Cognitive deficits in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006504.PUB2

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006504.PUB2

Mechanisms of Parkinson's disease linked to pathological alpha-synuclein: new targets for drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006504.PUB2

The medial temporal lobe in dementia with Lewy bodies: a comparative study with Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006504.PUB2

Cholinesterase inhibitors for Parkinson's disease dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006504.PUB2

The ten point clock test: a quick screen and grading method for cognitive impairment in medical and surgical patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006504.PUB2

Neuroleptic sensitivity in patients with senile dementia of Lewy body type

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006504.PUB2

Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006504.PUB2

Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006504.PUB2

Parkinson's disease: neuron loss in the nucleus basalis without concomitant Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006504.PUB2

Ubiquitin-proteasome system and Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006504.PUB2

A new rating scale for Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006504.PUB2

Cholinesterase inhibitors for dementia with Lewy bodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006504.PUB2

Olfactory impairment is more marked in patients with mild dementia with Lewy bodies than those with mild Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006504.PUB2

A systematic review of prevalence and incidence studies of dementia with Lewy bodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006504.PUB2

The cognitive drug research computerized assessment system for demented patients: A validation study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006504.PUB2

Special Topics in Statistics

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006504.PUB2

Patients with Lewy body dementia use more resources than those with Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006504.PUB2

7 January 2021

Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006504.PUB2

7 January 2021

Donepezil for behavioural disorders associated with Lewy bodies: a case series

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006504.PUB2

7 January 2021

Utility of the Mattis dementia rating scale to assess the efficacy of rivastigmine in dementia associated with Parkinson’s disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006504.PUB2

7 January 2021

Validity and reliability of the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change. The Alzheimer's Disease Cooperative Study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006504.PUB2

7 January 2021

Cholinesterase inhibition in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006504.PUB2

7 January 2021

Evaluating rivastigmine in mild-to-moderate Parkinson's disease dementia using ADAS-cog items.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006504.PUB2

7 January 2021

The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006504.PUB2

7 January 2021

Validity of the Trail Making Test as an Indicator of Organic Brain Damage

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006504.PUB2

7 January 2021

10.1002/14651858.CD006504.PUB2

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

5113824

Fatcat ID

release_7i26zzrfv5eotbqgtetaoiltt4

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/7i26zzrfv5eotbqgtetaoiltt4

24 November 2022

mapped directly with Wikidata item

OpenCitations bibliographic resource ID

5113824

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

1 reference

https://api.fatcat.wiki/v0/release/7i26zzrfv5eotbqgtetaoiltt4

24 November 2022